Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Da Vinci Xi robotic-assisted surgery for gastrointestinal stromal tumors: analysis of 20 mexican cases with regard to tumor size and location.

Created on 12 Nov 2026

Authors

Luis E García-Ríos, Marisol Luna-Castillo, Erick A Lopez-Herrera, Ma Guadalupe J De Anda-González, Rafael Medrano-Guzmán

Published in

Gaceta medica de Mexico. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Gastrointestinal stromal tumors (GIST) require R0 surgical resection as the standard treatment. Robotic surgery emerges as a promising alternative in complex cases, although no published series exist in Latin America.
The objective of the study was to evaluate robotic surgery in the treatment of GIST and the impact of tumor size and location on surgical outcomes.
Retrospective observational cohort study at the Oncology Hospital, Centro Médico Nacional Siglo XXI, Mexico City. Twenty patients with GIST underwent robotic surgery (da Vinci Xi) between January 2022 and December 2024, with follow-up until March 2025.
Mean age 65.2 years (10 men and 10 women). R0 resection was achieved in 100%, conversion rate to open surgery 5%, mean intraoperative blood loss was 101 mL, mean hospital stay 6.3 days, mean tumor size 5.47 cm, and post-operative morbidity 15%. Median follow-up 19 months: disease-free survival 100%.
Robotic resection of GIST in technically complex cases was safe and feasible in this first Mexican series.

PMID:
43013524
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement